Sep 23, 2024, 14:12
Rasha Aboelhassan: Future plans for HER2-positive breast cancer patients
Rasha Aboelhassan shared on Linkedin:
”One of the best things we get from discussing experts is knowing how they see the future.
During today’s Pfizer/Med Escape Symposium, I was excited about their mapping of future plans for HER2-positive breast cancer patients:
There are several changes coming that could change the guidelines.”
Source: Rasha Aboelhassan/Linkedin
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 22:37
Sep 2, 2025, 22:03
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54